Skip to main content
. Author manuscript; available in PMC: 2023 Jan 4.
Published in final edited form as: Mol Immunol. 2022 Apr 14;146:50–56. doi: 10.1016/j.molimm.2022.04.003

Fig. 5.

Fig. 5.

Effects of mutating the STAT3 sites on the synergy between IL-6 and IL-1β in inducing CRP promoter (Luc-157) activity. Hep3B cells were transfected with the WT and mutated CRP promoter-Luc constructs, as indicated on the x-axis, and treated with cytokines. Promoter activity was measured as transcription of the Luc reporter gene. The IL-6-induced CRP promoter-Luc activity for each construct is taken as 1 and the activity in response to the combination of IL-6 and IL-1β treatment is plotted as fold change over IL-6 activity. Data shown are mean ± SEM of three experiments. The differences between the WT and mutant promoters were not statistically significant (p > 0.05).